オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1 g - tablet, enteric coated - excipient ingredients: povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000 - salofalk tablets are indicated in the treatment of acute episodes and maintenance of remission of: i. mild to moderate ulcerative colitis; and ii. crohn?s ileitis and colitis

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hyprolose; povidone; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - colchicine, quantity: 500 microgram - tablet, uncoated - excipient ingredients: sodium starch glycollate; pregelatinised maize starch; lactose monohydrate; magnesium stearate; microcrystalline cellulose - relief of pain in acute gout. colchicine should not be used unless nsaids are contraindicated, or have been used and found to lack analgesic efficacy or to have unacceptable side effects in the individual patient. colchicine is not an analgesic and does not provide relief from other types of pain.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - colchicine, quantity: 500 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate - relief of pain in acute gout. colchicine should not be used unless nsaids are contraindicated, or have been used and found to lack analgesic efficacy or to have unacceptable side effects in the individual patient. colchicine is not an analgesic and does not provide relief from other types of pain.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - methotrexate sodium, quantity: 2.742 mg (equivalent: methotrexate, qty 2.5 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate - antineoplastic chemotherapy treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. chexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy (see warnings box and section 4.4) because of the high risk attending to its use, chexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations. rheumatoid arthritis chemotherapy (see warnings box and section 4.4) management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see section 4.4, and 4.5). steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - methotrexate sodium, quantity: 10.97 mg (equivalent: methotrexate, qty 10 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose - antineoplastic chemotherapy treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. chexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy (see warnings box and section 4.4) because of the high risk attending to its use, chexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations. rheumatoid arthritis chemotherapy (see warnings box and section 4.4) management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see section 4.4, and 4.5). steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - mesalazine, quantity: 800 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; purified talc; povidone; methacrylic acid copolymer; triethyl citrate; iron oxide yellow; iron oxide red; macrogol 6000 - for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - mesalazine, quantity: 400 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; purified talc; povidone; methacrylic acid copolymer; triethyl citrate; iron oxide yellow; iron oxide red; macrogol 6000 - for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - cladribine, quantity: 10 mg - tablet, uncoated - excipient ingredients: hydroxypropylbetadex; sorbitol; magnesium stearate - mavenclad is indicated for the treatment of relapsing-remitting multiple sclerosis (rrms) to reduce the frequency of clinical relapses and to delay the progression of physical disability.,following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4. re-initiation of therapy after year 4 has not been studied.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; povidone; sodium lauryl sulfate; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - ceptolate (mycophenolate mofetil) is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. ceptolate (mycophenolate mofetil) is indicated for the prophylaxis of organ rejection in paediatric patients with a body surface area of greater than or equal to 1.25 square metres, receiving allogeneic renal transplants.